IRONWOOD PHARMACEUTICALS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $3.24 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- IRONWOOD PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $3.24M, a 28.47% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $3.65M, a 30.96% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $3.61M, a 56.63% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $4.52M, a 47.21% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $29.85M, a 6.73% decline from fiscal 2023.
- IRONWOOD PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $32.01M, a 18.33% increase from fiscal 2022.
- IRONWOOD PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $27.05M, a 21.39% increase from fiscal 2021.
- IRONWOOD PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2021 was $22.28M, a 28.53% decline from fiscal 2020.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $3.24M 10-Q · filed 2026-08-06 | $6.89M derived: sum of 2 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $3.65M 10-Q · filed 2026-08-06 | ||||
| 2025-09-30 | $3.61M 10-Q · filed 2025-11-10 | $8.14M derived: sum of 2 quarters · filed 2026-08-06 | $13.43M derived: sum of 3 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $4.52M 10-Q · filed 2026-08-06 | $9.81M derived: sum of 2 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $5.29M 10-Q · filed 2026-08-06 | ||||
| 2024-12-31 | $29.85M 10-K · filed 2025-03-31 | ||||
| 2024-09-30 | $8.33M 10-Q · filed 2025-11-10 | $16.90M derived: sum of 2 quarters · filed 2025-11-10 | $25.28M derived: sum of 3 quarters · filed 2025-11-10 | ||
| 2024-06-30 | $8.57M 10-Q · filed 2025-11-10 | $16.95M derived: sum of 2 quarters · filed 2025-11-10 | |||
| 2024-03-31 | $8.38M 10-Q · filed 2025-11-10 | ||||
| 2023-12-31 | $32.01M 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | $7.91M 10-Q · filed 2024-11-07 | $16.17M derived: sum of 2 quarters · filed 2024-11-07 | $23.30M derived: sum of 3 quarters · filed 2024-11-07 | ||
| 2023-06-30 | $8.27M 10-Q · filed 2024-11-07 | $15.40M derived: sum of 2 quarters · filed 2024-11-07 | |||
| 2023-03-31 | $7.13M 10-Q · filed 2024-11-07 | ||||
| 2022-12-31 | $27.05M 10-K · filed 2025-03-31 | ||||
| 2022-09-30 | $7.07M 10-Q · filed 2023-11-09 | $13.67M derived: sum of 2 quarters · filed 2023-11-09 | $19.76M derived: sum of 3 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $6.60M 10-Q · filed 2023-11-09 | $12.69M derived: sum of 2 quarters · filed 2023-11-09 | |||
| 2022-03-31 | $6.09M 10-Q · filed 2023-11-09 | ||||
| 2021-12-31 | $22.28M 10-K · filed 2024-02-16 | ||||
| 2021-09-30 | $6.21M 10-Q · filed 2022-11-03 | $10.79M derived: sum of 2 quarters · filed 2022-11-03 | $16.19M derived: sum of 3 quarters · filed 2022-11-03 | ||
| 2021-06-30 | $4.59M 10-Q · filed 2022-11-03 | $9.98M derived: sum of 2 quarters · filed 2022-11-03 | |||
| 2021-03-31 | $5.40M 10-Q · filed 2022-11-03 | ||||
| 2020-12-31 | $31.18M 10-K · filed 2023-02-16 | ||||
| 2020-09-30 | $7.71M 10-Q · filed 2021-11-04 | $14.80M derived: sum of 2 quarters · filed 2021-11-04 | $21.17M derived: sum of 3 quarters · filed 2021-11-04 | ||
| 2020-06-30 | $7.09M 10-Q · filed 2021-11-04 | $13.46M derived: sum of 2 quarters · filed 2021-11-04 | |||
| 2020-03-31 | $6.36M 10-Q · filed 2021-11-04 | ||||
| 2019-12-31 | -$32.33M 10-K · filed 2022-02-18 | $32.33M 10-K · filed 2020-02-13 | |||
| 2019-09-30 | $5.52M 10-Q · filed 2020-11-05 | $11.86M derived: sum of 2 quarters · filed 2020-11-05 | $26.84M derived: sum of 3 quarters · filed 2020-11-05 | ||
| 2019-06-30 | $6.34M 10-Q · filed 2020-11-05 | $21.32M derived: sum of 2 quarters · filed 2020-11-05 | |||
| 2019-03-31 | $14.99M 10-Q · filed 2020-11-05 | ||||
| 2018-12-31 | $44.01M 10-K · filed 2021-02-17 | ||||
| 2018-09-30 | $12.65M 10-Q · filed 2019-10-31 | $23.22M derived: sum of 2 quarters · filed 2019-10-31 | $32.28M derived: sum of 3 quarters · filed 2019-10-31 | ||
| 2018-06-30 | $10.57M 10-Q · filed 2019-10-31 | $19.63M derived: sum of 2 quarters · filed 2019-10-31 | |||
| 2018-03-31 | $9.06M 10-Q · filed 2019-10-31 | ||||
| 2017-12-31 | $33.51M 10-K · filed 2020-02-13 | ||||
| 2016-12-31 | $28.67M 10-K · filed 2019-02-25 | ||||
| 2015-12-31 | $25.45M 10-K · filed 2018-02-22 | ||||
| 2014-12-31 | $23.57M 10-K · filed 2017-02-22 | ||||
| 2013-12-31 | $19.62M 10-K · filed 2016-02-19 | ||||
| 2012-12-31 | $17.48M 10-K · filed 2015-02-18 | ||||
| 2011-12-31 | $11.55M 10-K · filed 2014-02-07 | ||||
| 2010-12-31 | $7.11M 10-K · filed 2013-02-21 | ||||
| 2009-12-31 | $4.79M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |